• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

News

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact

News · January 13, 2022

Syndivia and TVM Capital Life Science Announce Creation of Auricula Biosciences to Develop Innovative Therapy for Patients with K-Ras mutant malignancies

laboratory

Luxembourg, January 13th, 2022 – TVM Life Science Innovation II SCSp announced the Fund's investment establishing Auricula Biosciences, Inc., a company based in Wilmington, Delaware, USA. Auricula …

News · November 22, 2021

Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update

laboratory

NEWTON, MA – Nov. 19, 2021 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and …

News · November 16, 2021

Kent Imaging – Setting A New Global Standard in Advanced Tissue Assessment

handheld-kent-imaging

November 16, 2021 Kent Imaging is a market leader in light-based tissue assessment diagnostic devices. The company designs and manufactures imaging technology that supports real-time …

News · November 16, 2021

Nekonal and TVM Capital Life Science Announce Creation of T7 Therapeutics to Develop Innovative Therapy for Patients with Auto-immune diseases

laboratory

Luxembourg, November 15th, 2021 – TVM Life Science Innovation II SCSp announced the Fund's investment establishing T7 Therapeutics, Inc., a company based in Wilmington, Delaware, USA. T7 …

News · October 8, 2021

CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases

centogene

Combining Expertise to Advance Precision Medicine, While Enabling a More Efficient and Timely Diagnosis of Rare Diseases Around the World CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and SOUTH …

News · October 8, 2021

Acer Therapeutics Receives Notice of Allowance of Key U.S. Patent Application Covering ACER-001 Formulation

laboratory

Notice of allowance of ACER-001 formulation composition of matter patent application strengthens proprietary position in U.S. until 2036 NEWTON, MA and GENEVA, SWITZERLAND – October 7, 2021 – Acer …

News · July 15, 2021

Rapid Micro Biosystems Announces Pricing of Initial Public Offering

Source: Rapid Micro Biosystems, Inc.July 14, 2021 21:30 ETLOWELL, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (“RapidMicro”), an innovative life sciences …

News · May 27, 2021

Acer Therapeutics Plans NDA Submission for ACER-001 in Q3 2021
Following Pre-NDA Meeting with FDA

laboratory

NEWTON, MA and GENEVA, SWITZERLAND – May 25, 2021 – Acer Therapeutics Inc. (Nasdaq: ACER)(“Acer”), a pharmaceutical company focused on the acquisition, development and commercialization of therapies …

News · March 25, 2021

COVID Innovations March 25th, 2021

Author: Dr. Linda Morrow – March 25th, 2021 Imagine a pandemic without having to shut down our lives. Imagine governments and industry working cooperatively to develop diagnostic and vaccine …

News · March 22, 2021

Relief and Acer Therapeutics Sign Collaboration and License Agreement for Worldwide Development and Commercialization of ACER-001 for the Treatment of Urea Cycle Disorders and Maple Syrup Urine Disease

laboratory

Relief to potentially pay Acer up to $36 million and royalties in exchange for net profit share and territory rights ACER-001 pre-NDA meeting with U.S. FDA scheduled in Q2 2021 GENEVA, SWITZERLAND and …

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Interim pages omitted …
  • Go to page 31
  • Go to Next Page »

Primary Sidebar

Secondary Sidebar

Additional News

Panthera D-SAD Classic oral appliance now eligible for Medicare reimbursement

August 1, 2022

Kent Imaging Recognized as Most Innovative Medical Imaging Technology Developer in Canada

June 23, 2022

Egg Medical hatches technology to shield health care workers from radiation

March 29, 2022

Egg Medical hatches $13M VC funding

March 15, 2022

Egg Medical, Inc., Closes on $13 million Financing

March 3, 2022

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact